Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

导出 OA

翻译打印收藏纠错

作者： George L,Chen ^[1] ; Paul A,Carpenter ^[2] ; Raewyn,Broady ^[3] ; Tara K,Gregory ^[4] ; Laura J,Johnston ^[5] ; Barry E,Storer ^[6] ; Jan H,Beumer ^[7] ; Jingxin,Qiu ^[1] ; Kiara,Cerda ^[5] ; Ryan,Le ^[5] ; Joanne M,Otani ^[5] ; Hong,Liu ^[8] ; Maureen A,Ross ^[1] ; Sally,Arai ^[5] ; Mary E D,Flowers ^[2] ; Philip L,McCarthy ^[1] ; David B,Miklos ^[9]

作者单位： Medicine/BMT Program and Pathology, Roswell Park Cancer Institute, Buffalo, New York. ^[1] Department of Pediatrics, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[2] Department of Medicine, Leukemia BMT Program of British Columbia, Vancouver, British Columbia, Canada. ^[3] Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, Colorado. ^[4] Department of Medicine, Medicine/BMT Division, Stanford University School of Medicine, Stanford, California. ^[5] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[6] School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[7] Buffalo Medical Group, Buffalo, New York. ^[8] Department of Medicine, Medicine/BMT Division, Stanford University School of Medicine, Stanford, California. Electronic address: dmiklos@stanford.edu. ^[9]

关键词 Chronic graft-versus-host disease Clinical trial Nilotinib